Caris Life Sciences announces Vall d´Hebron Institute of Oncology joins its precision oncology alliance

▴ Caris Life Sciences announces Vall d´Hebron Institute of Oncology joins its precision oncology alliance
The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research

Caris Life Sciences, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Spain's Vall d´Hebron Institute of Oncology (VHIO) has joined Caris' Precision Oncology Alliance (The Alliance/POA). The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.

Established in 2006, VHIO is a leading comprehensive research cancer center of excellence, where scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. Undertaking one of Spain´s most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments and better practice for the care of their patients.

"We are excited to welcome the Vall d' Hebron Institute of Oncology into the Alliance as we begin to expand the Caris POA network outside the U.S.," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "International members like VHIO, focused on advancing personalized and targeted therapies against cancer through innovation and research, support the Alliance's goal to expand broad-based collaboration among our member institutions in precision oncology research to improve outcomes for cancer patients worldwide."

"Our mission to provide improvements in the field of oncological diseases, and translate discoveries into medical benefits is enriched through partnerships like the Caris Precision Oncology Alliance. I strongly believe in joining forces, nurturing and developing partnerships, and exchanging data to overcome the many challenges that hamper our efforts in solving cancer sooner," said Josep Tabernero, M.D., Ph.D., VHIO's Director. "Understanding the unique molecular characteristics of tumors offers insights that can be used to better prevent and treat cancer for patients everywhere."

The Caris Precision Oncology Alliance includes over 40 cancer centers and academic institutions. These institutions have early access to Caris MAI (Molecular Artificial Intelligence) offerings, and establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence platform, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by Biopharma.

"Partnering with international institutes like Vall d'Hebron Institute of Oncology expands the capabilities for all Alliance members to access pioneering research that can both advance and accelerate personalized and targeted therapies to better treat cancer," said Brian J. Brille, Vice Chairman of Caris Life Sciences.

Tags : #CarisLifeSciences #LatestNewsonCarisLifeSciences1stDec #ValldHebronInstituteofOncology #LatestPharmaNews1stDec #LatestPharmaCollaboration1stDec #LatestNewsonCancerResearch1stDec #MolecularScience #Spain

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

SARV Events & Celebrations Shines at "Edu-Bizz Leadership Summit & Awards 24July 18, 2024
UAE launches global initiative to build 10 hospitals to address critical healthcare gaps as part of Zayed Humanitarian Legacy InitiativeJuly 18, 2024
Geetanjali Homestate Expands Global Presence with the Launch of Geetanjali GlobalJuly 18, 2024
Changes projected in marine fish communities due to climate changeJuly 18, 2024
Understanding the Chandipura Virus Outbreak in Gujarat: A Critical OverviewJuly 18, 2024
Landmark Study Links Severe Endometriosis to Increased Risk of Ovarian CancerJuly 18, 2024
Equipping Healthcare Professionals for Global Opportunities: GIMS Partners with NSDCJuly 18, 2024
Hormone Modulating Therapy for Breast Cancer and Its Link to Lower Alzheimer’s RiskJuly 18, 2024
Multipl Secures $1.5 Million in Additional Funds, Led by Blume Ventures and MIXI Global Investments, JapanJuly 17, 2024
FedEx to empower youth with digital skilling programJuly 17, 2024
Putting people first means following Gandhi's TalismanJuly 17, 2024
American Oncology Institute (AOI) Launches #BreaktheHabit Campaign to Raise Awareness on Head & Neck cancerJuly 17, 2024
Chamraj Tea Estate Launches New Nilgiri Tea Blends: ‘Master Blend,’ ‘Master Blend Ginger Tea,’ and ‘Master Blend Lemon Tea’July 16, 2024
How a Fiber-Rich Diet and Gut Parasites Can Improve Your HealthJuly 16, 2024
LinkedIn: A Double-Edged Sword for Professional GrowthJuly 16, 2024
Food Safety and Drug Administration (FDA), Uttarakhand, National Association of Street Vendors of India (NASVI) and Nestlé India expand Project ‘Serve Safe Food’ in Uttarakhand July 16, 2024
IIT Kharagpur and University of Leeds Sign MoU for Joint Supervision of PhD ProgramsJuly 16, 2024
Puja Curtains go up with KHUTI PUJA at Hazra Park DurgotsabJuly 16, 2024
Algorand and SEWA Join Forces to Launch Digital Health Passport Initiative for Women's EmpowermentJuly 15, 2024
The Debate Over Menstrual Leave: Balancing Needs and Workplace EqualityJuly 15, 2024